Cargando…
Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia
INTRODUCTION: Across the world, health systems are adopting approaches to manage rising healthcare costs. One common strategy is a medication copayments scheme where consumers make a contribution (copayment) towards the cost of their dispensed medicines, with remaining costs subsidised by the health...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577882/ https://www.ncbi.nlm.nih.gov/pubmed/28637723 http://dx.doi.org/10.1136/bmjopen-2016-013691 |
_version_ | 1783260432367091712 |
---|---|
author | Seaman, Karla L Sanfilippo, Frank M Roughead, Elizabeth E Bulsara, Max K Kemp-Casey, Anna Bulsara, Caroline Watts, Gerald F Preen, David |
author_facet | Seaman, Karla L Sanfilippo, Frank M Roughead, Elizabeth E Bulsara, Max K Kemp-Casey, Anna Bulsara, Caroline Watts, Gerald F Preen, David |
author_sort | Seaman, Karla L |
collection | PubMed |
description | INTRODUCTION: Across the world, health systems are adopting approaches to manage rising healthcare costs. One common strategy is a medication copayments scheme where consumers make a contribution (copayment) towards the cost of their dispensed medicines, with remaining costs subsidised by the health insurance service, which in Australia is the Federal Government. In Australia, copayments have tended to increase in proportion to inflation, but in January 2005, the copayment increased substantially more than inflation. Results from aggregated dispensing data showed that this increase led to a significant decrease in the use of several medicines. The aim of this study is to determine the demographic and clinical characteristics of individuals ceasing or reducing statin medication use following the January 2005 Pharmaceutical Benefit Scheme (PBS) copayment increase and the effects on their health outcomes. METHODS AND ANALYSIS: This whole-of-population study comprises a series of retrospective, observational investigations using linked administrative health data on a cohort of West Australians (WA) who had at least one statin dispensed between 1 May 2002 and 30 June 2010. Individual-level data on the use of pharmaceuticals, general practitioner (GP) visits, hospitalisations and death are used. This study will identify patients who were stable users of statin medication in 2004 with follow-up commencing from 2005 onwards. Subgroups determined by change in adherence levels of statin medication from 2004 to 2005 will be classified as continuation, reduction or cessation of statin therapy and explored for differences in health outcomes and health service utilisation after the 2005 copayment change. ETHICS AND DISSEMINATION: Ethics approvals have been obtained from the Western Australian Department of Health (#2007/33), University of Western Australia (RA/4/1/1775) and University of Notre Dame (0 14 167F). Outputs from the findings will be published in peer reviewed journals designed for a policy audience and presented at state, national and international conferences. |
format | Online Article Text |
id | pubmed-5577882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-55778822017-09-08 Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia Seaman, Karla L Sanfilippo, Frank M Roughead, Elizabeth E Bulsara, Max K Kemp-Casey, Anna Bulsara, Caroline Watts, Gerald F Preen, David BMJ Open Health Policy INTRODUCTION: Across the world, health systems are adopting approaches to manage rising healthcare costs. One common strategy is a medication copayments scheme where consumers make a contribution (copayment) towards the cost of their dispensed medicines, with remaining costs subsidised by the health insurance service, which in Australia is the Federal Government. In Australia, copayments have tended to increase in proportion to inflation, but in January 2005, the copayment increased substantially more than inflation. Results from aggregated dispensing data showed that this increase led to a significant decrease in the use of several medicines. The aim of this study is to determine the demographic and clinical characteristics of individuals ceasing or reducing statin medication use following the January 2005 Pharmaceutical Benefit Scheme (PBS) copayment increase and the effects on their health outcomes. METHODS AND ANALYSIS: This whole-of-population study comprises a series of retrospective, observational investigations using linked administrative health data on a cohort of West Australians (WA) who had at least one statin dispensed between 1 May 2002 and 30 June 2010. Individual-level data on the use of pharmaceuticals, general practitioner (GP) visits, hospitalisations and death are used. This study will identify patients who were stable users of statin medication in 2004 with follow-up commencing from 2005 onwards. Subgroups determined by change in adherence levels of statin medication from 2004 to 2005 will be classified as continuation, reduction or cessation of statin therapy and explored for differences in health outcomes and health service utilisation after the 2005 copayment change. ETHICS AND DISSEMINATION: Ethics approvals have been obtained from the Western Australian Department of Health (#2007/33), University of Western Australia (RA/4/1/1775) and University of Notre Dame (0 14 167F). Outputs from the findings will be published in peer reviewed journals designed for a policy audience and presented at state, national and international conferences. BMJ Publishing Group 2017-06-21 /pmc/articles/PMC5577882/ /pubmed/28637723 http://dx.doi.org/10.1136/bmjopen-2016-013691 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Health Policy Seaman, Karla L Sanfilippo, Frank M Roughead, Elizabeth E Bulsara, Max K Kemp-Casey, Anna Bulsara, Caroline Watts, Gerald F Preen, David Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia |
title | Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia |
title_full | Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia |
title_fullStr | Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia |
title_full_unstemmed | Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia |
title_short | Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia |
title_sort | impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from western australia |
topic | Health Policy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577882/ https://www.ncbi.nlm.nih.gov/pubmed/28637723 http://dx.doi.org/10.1136/bmjopen-2016-013691 |
work_keys_str_mv | AT seamankarlal impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia AT sanfilippofrankm impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia AT rougheadelizabethe impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia AT bulsaramaxk impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia AT kempcaseyanna impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia AT bulsaracaroline impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia AT wattsgeraldf impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia AT preendavid impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia |